← Banking With Billy News

Humacyte said the FDA accepted its IND, clearing the start of a first-in-human trial of its Coronary Tissue Engineered Vessel for coronary bypass surgery. The c

BWB News TV • 2026-07-29 15:13 UTC • By Billy Odell Tucker-Robinson
Humacyte said the FDA accepted its IND, clearing the start of a first-in-human trial of its Coronary Tissue Engineered Vessel for coronary bypass surgery. The c
Humacyte said the FDA accepted its IND, clearing the start of a first-in-human trial of its Coronary Tissue Engineered Vessel for coronary bypass surgery. The candidate is positioned as a first-in-class graft for coronary artery disease.
Share this article
𝕏 X / Twitter Facebook LinkedIn WhatsApp
📚 More from Billy’s World
📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly